

Supplemental online content for:

## Harmonized Outcome Measures for Use in Non–Small Cell Lung Cancer Patient Registries and Clinical Practice

Martin J. Edelman, MD; Daniel P. Raymond, MD; Dwight H. Owen, MD, MS; Michelle B. Leavy, MPH; Kari Chansky, MS; Sriram Yennu, MD; Felix G. Fernandez, MD, MSc; Carolyn J. Presley, MD, MHS; Tithi Biswas, MD; Gwendolyn P. Quinn, PhD; Matthew B. Schabath, PhD; Seth Sheffler-Collins, MPH; Laura Chu, MPH; and Richard E. Gliklich, MD

*J Natl Compr Canc Netw*, doi: 10.6004/jnccn.2021.7021

**eTable 1:** Invited Registries/Initiatives That Declined to Participate

**eTable 1. Invited Registries/Initiatives That Declined to Participate**

Initiative/Registry Name	Sponsoring Organization	Primary Purpose
A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer (ClinicalTrials.gov identifier: NCT03047616)	Abramson Cancer Center of the University of Pennsylvania	To broadly discover and evaluate the utility of blood-based biomarkers for use in measuring and predicting response to immunotherapy in patients with lung cancer.
NYS Cancer Registry	NYS	To collect information on new cases and cancer deaths in NYS.
The Lung Cancer Registry	GO2 Foundation for Lung Cancer, American Lung Association, and the IASLC	To develop a robust source of data on patients with lung cancer to support research to improve diagnosis, treatment, and patient outcomes.
Lung Cancer Screening Registry	American College of Radiology	To improve quality of care and outcomes for patients undergoing CT lung cancer screening. The registry is a QCDR and meets quality reporting requirements for the CMS.
CCR	State of California	To collect information about cancers diagnosed in California to improve understanding of cancer and to develop strategies and policies for its prevention, treatment, and control.
Safety profiles of patients with NSCLC treated with pemetrexed + carboplatin: a real-world retrospective, observational, cohort study (doi.org/10.1080/03007995.2017.1297700)	Eli Lilly and Company	To examine the characteristics and safety profile of a NSCLC population treated with PCb area under the concentration-time curve 5 (PCb5) or 6 (PCb6) under real-world conditions.

Abbreviations: CCR, California Cancer Registry; CMS, Centers for Medicare & Medicaid Services; IASLC, International Association for the Study of Lung Cancer; NSCLC, non-small cell lung cancer; NYS, New York State; PCb, paclitaxel + carboplatin; PCb5, PCb at 5 mg/mL•min; PCb6, PCb at 6 mg/mL•min; QCDR, qualified clinical data registry.